Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Clinical trial NCT04913337 · UNKNOWN

Trial details

NCT number: NCT04913337
Sponsor: NGM Biopharmaceuticals, Inc
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Mesothelioma Glioblastoma Renal Cell Carcinoma Non Small Cell Lung Cancer Melanoma Pancreatic Ductal Adenocarcinoma Gastric Cancer Squamous Cell Carcinoma of Head and Neck Cholangiocarcinoma Breast Cancer Ovarian Cancer Cervical Cancer

Start date: 2021-06-09
Primary completion: 2025-02-01
Enrollment: 179

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.